Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18610978 | ANTIBODIES TARGETING CELL SURFACE DEPOSITED COMPLEMENT PROTEIN C3d AND USE THEREOF | March 2024 | March 2026 | Abandon | 24 | 2 | 1 | No | No |
| 18296452 | METHODS OF IMPROVING THE THERAPEUTIC INDEX | April 2023 | January 2026 | Abandon | 33 | 2 | 1 | No | No |
| 18050845 | COMPOSITIONS AND METHODS FOR CO-POTENTIATION OF CD3 TO TREAT A VIRAL INFECTION AND INCREASE THE IMMUNE RESPONSE AGAINST A VIRAL ANTIGEN | October 2022 | October 2025 | Abandon | 36 | 2 | 1 | No | No |
| 17823003 | Engineered Cytolytic Immunecell | August 2022 | August 2025 | Allow | 35 | 0 | 0 | No | No |
| 17861177 | MODIFIED CD20 ANTIBODIES AND USES THEREOF | July 2022 | April 2025 | Abandon | 33 | 1 | 0 | No | No |
| 17849399 | HUMANIZED BCMA ANTIBODY AND BCMA-CAR-T CELLS | June 2022 | October 2025 | Allow | 40 | 1 | 0 | No | No |
| 17842914 | Anti-claudin 6 Antibody and Antibody-drug Conjugate | June 2022 | October 2025 | Allow | 40 | 1 | 0 | No | No |
| 17786265 | USES OF ANTI-TGF-BETA ANTIBODIES AND CHECKPOINT INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | June 2022 | February 2026 | Abandon | 44 | 1 | 0 | No | No |
| 17778636 | MONOCLONAL ANTIBODIES THAT TARGET HUMAN CD47 PROTEIN | May 2022 | December 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17777596 | A NOVEL ANTI-CD3/ANTI-EGFR BISPECIFIC ANTIBODY AND USES THEREOF | May 2022 | December 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17714847 | TREATMENTS FOR PRURIGO NODULARIS | April 2022 | January 2026 | Allow | 46 | 3 | 1 | Yes | No |
| 17764503 | AMIDE-LINKED, AMINOBENZAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | March 2022 | December 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17762148 | ANTI-EPHA10 ANTIBODIES AND METHODS OF USE THEREOF | March 2022 | November 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17631641 | FORMULATION COMPRISING ANTI-PD-1/HER2 BISPECIFIC ANTIBODY, METHOD FOR PREPARING SAME AND USE THEREOF | January 2022 | February 2026 | Allow | 48 | 1 | 1 | Yes | No |
| 17572039 | TETRAVALENT BISPECIFIC ANTIBODY AGAINST PD-1/LAG-3, PREPARATION METHOD THEREFOR, AND USE THEREOF | January 2022 | August 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17625925 | COMPOSITION FOR PREVENTING, AMELIORATING OR TREATING IMMUNE CHECKPOINT INHIBITOR-RESISTANT CANCER | January 2022 | November 2025 | Abandon | 46 | 1 | 0 | No | No |
| 17620290 | ANTI-CD3E/BCMA BISPECIFIC ANTIBODY AND USE THEREOF | December 2021 | October 2025 | Allow | 46 | 1 | 1 | No | No |
| 17552383 | ANTI-IL5R ANTIBODY FORMULATIONS | December 2021 | July 2025 | Abandon | 43 | 1 | 1 | No | No |
| 17596596 | Bispecific Chimeric Antigen Receptor | December 2021 | June 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17618922 | INHIBITION OF SIRP-GAMMA FOR CANCER TREATMENT | December 2021 | December 2025 | Allow | 48 | 3 | 0 | Yes | No |
| 17617046 | HIGH AFFINITY ANTI-CD3 ANTIBODIES, AND METHODS FOR THEIR GENERATION AND USE | December 2021 | October 2025 | Allow | 46 | 1 | 1 | No | No |
| 17616274 | ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS THAT TARGET TACI | December 2021 | December 2025 | Allow | 48 | 1 | 1 | Yes | No |
| 17616373 | ANTI-T CELL ANTIGEN-BINDING MOLECULE TO BE USED IN COMBINATION WITH CYTOKINE INHIBITOR | December 2021 | June 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17615832 | ANTIBODY AND BISPECIFIC ANTIBODY TARGETING LAG-3 AND USE THEREOF | December 2021 | January 2026 | Allow | 49 | 2 | 1 | Yes | No |
| 17613251 | ANTI-ROR1 / ANTI-CD3 BISPECIFIC BINDING MOLECULES | November 2021 | March 2026 | Allow | 51 | 2 | 1 | No | No |
| 17612877 | Uses of Radiation and Benzodiazepine Derivatives in Cancer Therapies | November 2021 | March 2026 | Allow | 52 | 2 | 1 | No | No |
| 17530302 | ANTI-SIRPalpha MONOCLONAL ANTIBODIES AND USES THEREOF | November 2021 | March 2025 | Allow | 40 | 1 | 0 | Yes | No |
| 17522189 | ANTI-CD166 ANTIBODIES AND USES THEREOF | November 2021 | May 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17609053 | HUMANIZED ANTIBODIES TO MUCIN-16 AND METHODS OF USE THEREOF | November 2021 | October 2025 | Allow | 47 | 1 | 1 | Yes | No |
| 17608204 | METHOD OF PRODUCING A RECOMBINANT PROTEIN | November 2021 | September 2025 | Abandon | 46 | 1 | 0 | No | No |
| 17608056 | BIOLOGICAL BINDING MOLECULES | November 2021 | March 2026 | Allow | 52 | 1 | 1 | Yes | No |
| 17607641 | ALLOGENEIC CELL THERAPY OF B CELL MALIGNANCIES USING GENETICALLY ENGINEERED T CELLS TARGETING CD19 | October 2021 | September 2025 | Abandon | 47 | 1 | 0 | No | No |
| 17452033 | FUSION PROTEIN OF SINGLE DOMAIN ANTIBODY AND PROCOAGULANT | October 2021 | April 2025 | Allow | 42 | 1 | 1 | No | No |
| 17499030 | Bispecific Antibody Compositions and Methods for Treating COVID-19 | October 2021 | July 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17290728 | HOMODIMER-TYPE BISPECIFIC ANTIBODY AGAINST HER2 AND CD3 AND USE THEREOF | October 2021 | February 2026 | Abandon | 58 | 2 | 1 | No | No |
| 17600904 | IMMUNE CELL CONTAINING TUMOR ANTIGEN RECOGNITION RECEPTOR AND APPLICATION THEREOF | October 2021 | October 2025 | Abandon | 48 | 1 | 1 | No | No |
| 17600300 | METHODS FOR DIAGNOSING AND TREATING INFLAMMATORY BOWEL DISEASE IN COMPANION ANIMALS | September 2021 | June 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17599875 | ANTIBODIES AGAINST PROGRAMMED CELL DEATH PROTEIN 1 (PD1) AND USES THEREOF | September 2021 | July 2025 | Allow | 45 | 1 | 0 | No | No |
| 17441960 | TREATMENT OF TAUPATHY DISORDERS BY TARGETING NEW TAU SPECIES | September 2021 | March 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17429090 | GLUCURONOXYLOMANNAN (GXM) RECEPTOR CHIMERIC ANTIGEN RECEPTORS AND USE THEREOF | August 2021 | April 2025 | Allow | 45 | 1 | 0 | No | No |
| 17422523 | HUMAN IMMUNODEFICIENCY VIRUS-SPECIFIC T CELL RECEPTORS | July 2021 | April 2025 | Allow | 45 | 1 | 1 | Yes | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner HOPKINS, SAMANTHA LAKE works in Art Unit 1641 and has examined 25 patent applications in our dataset. With an allowance rate of 56.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 46 months.
Examiner HOPKINS, SAMANTHA LAKE's allowance rate of 56.0% places them in the 17% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by HOPKINS, SAMANTHA LAKE receive 1.04 office actions before reaching final disposition. This places the examiner in the 10% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by HOPKINS, SAMANTHA LAKE is 46 months. This places the examiner in the 10% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +61.1% benefit to allowance rate for applications examined by HOPKINS, SAMANTHA LAKE. This interview benefit is in the 97% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 50.0% of applications are subsequently allowed. This success rate is in the 96% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 0.0% of cases where such amendments are filed. This entry rate is in the 0% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants file petitions regarding this examiner's actions, 100.0% are granted (fully or in part). This grant rate is in the 90% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.